Thymidine kinase: the future in breast cancer prognosis
Thymidine kinase: the future in breast cancer prognosis
复制标题
DOI：
10.1016/0960-9776(95)90000-4
复制
发表时间：
1995-06
期刊：
影响因子：
--
通讯作者：
K. O’Neill;R. V. Grigsby;D. Fairbairn
中科院分区：
文献类型：
--
作者：
K. O’Neill;R. V. Grigsby;D. Fairbairn
准确描述人类乳腺癌中肿瘤侵袭性的能力是不够的。目前的预后指标，虽然有用，但不能准确预测肿瘤的行为。因此，需要进行多变量分析，以从广泛的指标中获得任何有意义的值。预后指征通常由原发肿瘤确定，但真实的预后价值取决于潜在转移性病变的活性。我们在这篇论文中提出的证据，使用胸苷激酶，一种酶的细胞增殖的指示，作为一种肿瘤标志物与个人的预后价值。以前已经确定，乳腺癌患者的肿瘤和血清中的胸苷激酶水平在临床研究中已显示与肿瘤分期呈正相关。系列血清样本的监测也被证明在预测治疗反应方面具有预后价值。原发性肿瘤中胸苷激酶水平的测量已被证明是肿瘤复发的预测因子。我们建议，一个更准确的方法来测量胸苷激酶活性的发展可能会显着帮助乳腺癌的管理，同时消除目前的放射性标记检测系统的检测问题。这可以通过包括基于免疫学的检测系统来完成。
The ability to precisely describe tumour aggressiveness in human breast cancer is inadequate. Current prognostic indicators, although useful, cannot accurately predict tumour behavior. As a result, multivariate analyses are required to obtain any significant value from a wide rangeastic indicators. Prognostic indications are generally determined from the primary tumour, but real prognostic value is dependent upon the activity of potentially metastatic lesions. We present in this paper evidence for the use of thymidine kinase, an enzyme indicative of cellular proliferation, as a tumour marker with individual prognostic value. It has been previously established that thymidine kinase levels in both tumours and sera of patients with breast cancer have been shown in clinical studies to be positively correlated with tumour stage. The monitoring of serial serum samples has also proven to be of prognostic value in predicting response to therapy. Measurements of thymidine kinase levels in primary tumours have demonstrated utility as a predictor of tumour recurrence. We propose that the development of a more accurate method of measuring thymidine kinase activity may aid significantly in the management of breast cancer, while eliminating the current detection problems of radio-labeling assay systems. This can be done by the inclusion of an immunologically based detection system.